FDA grants fast track status to Innovent’s IBI363 for melanoma
The US Food and Drug Administration (FDA) has granted fast track designation to Innovent Biologics' IBI363 for treating melanoma.
The US Food and Drug Administration (FDA) has granted fast track designation to Innovent Biologics' IBI363 for treating melanoma.
What's Your Reaction?
